Clinical and radiological outcomes of core decompression for early osteonecrosis of the femoral head: a retrospective comparative study

Shekhar P. Malve; Utkarsh K. Vishwakarma; Sunil G. Kulkarni

doi:10.18203/issn.2455-4510.IntJResOrthop20262918

Authors

Shekhar P. Malve Department of Orthopaedics, Post Graduate Institute of Swasthiyog, Pratishthan, Miraj, Maharashtra, India https://orcid.org/0009-0002-6477-3486
Utkarsh K. Vishwakarma Department of Orthopaedics, Post Graduate Institute of Swasthiyog, Pratishthan, Miraj, Maharashtra, India https://orcid.org/0009-0001-6906-0867
Sunil G. Kulkarni Department of Orthopaedics, Post Graduate Institute of Swasthiyog, Pratishthan, Miraj, Maharashtra, India https://orcid.org/0000-0003-3444-9976

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20262918

Keywords:

Bone grafting, Core decompression, Hip preservation, Harris hip score, Modified ficat arlet staging, Osteonecrosis of femoral head, Platelet-rich plasma, Total hip arthroplasty

Abstract

Background: Osteonecrosis of the femoral head (ONFH) is a progressive disorder characterized by compromised blood supply, leading to femoral head collapse and secondary osteoarthritis. As the disease predominantly affects young adults, hip-preserving procedures remain the preferred treatment in pre-collapse stages. Core decompression (CD) with bone grafting is widely performed, while platelet-rich plasma (PRP) has emerged as a biological adjunct that may enhance angiogenesis and osteogenesis. This study compared the clinical and radiological outcomes of core decompression with bone grafting alone versus core decompression with bone grafting augmented with PRP.

Methods: This retrospective comparative study included 75 patients (78 hips) with ONFH treated between January 2015 and December 2024. Group A comprised 35 patients treated with core decompression and cancellous bone grafting, while Group B included 40 patients treated with core decompression, cancellous bone grafting and PRP. Clinical outcomes were assessed using the Harris hip score (HHS) and radiographic progression and conversion to total hip arthroplasty (THA) were recorded.

Results: Good-to-excellent outcomes were achieved in 77.5% of the PRP group compared with 57.1% of the conventional group. Poor functional outcomes were observed in 17.5% of the PRP group compared to 37.1% of the conventional group. THA conversion was lower in the PRP group (17.1%) as compared to the conventional group (35.1%), representing an 18.0% absolute risk reduction.

Conclusions: PRP augmentation demonstrated improved functional outcomes and reduced conversion to THA compared with bone grafting alone, suggesting a promising biological adjunct for hip preservation in early-stage ONFH.

Metrics

Metrics Loading ...

References

Karl Moya-Angeler J, Gianakos AL, Villa JC, Ni A, Lane JM. Current concepts on osteonecrosis of the femoral head. World J Orthop. 2015;18;6(8):590-601. DOI: https://doi.org/10.5312/wjo.v6.i8.590

Mont MA, Salem HS, Piuzzi NS, Goodman SB, Jones LC. Nontraumatic osteonecrosis of the femoral head: where do we stand today: a 5-year update. J Bone Joint Surg Am. 2020;17;102(12):1084-99. DOI: https://doi.org/10.2106/JBJS.19.01271

Zhao D, Zhang F, Wang B, Liu B, Li L, Kim SY, et al. Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version). J Orthop Transl. 2020;21:100-10. DOI: https://doi.org/10.1016/j.jot.2019.12.004

Cardín-Pereda A, García-Sánchez D, Terán-Villagrá N, Alfonso-Fernández A, Fakkas M, Garcés-Zarzalejo C, et al. Osteonecrosis of the femoral head: a multidisciplinary approach in diagnostic accuracy. Diagnostics. 2022;12(7):1731. DOI: https://doi.org/10.3390/diagnostics12071731

Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124. DOI: https://doi.org/10.1053/sarh.2002.33724b

Yoon BH, Mont MA, Koo KH, Chen CH, Cheng EY, Cui Q, et al. The 2019 revised version of association research circulation osseous staging system of osteonecrosis of the femoral head. J Arthroplasty. 2020;35(4):933-40. DOI: https://doi.org/10.1016/j.arth.2019.11.029

Steinberg ME, Steinberg DR. Evaluation and staging of avascular necrosis. Semin Arthroplasty. 1991;2(3):175–81.

Lieberman JR, Engstrom SM, Meneghini MR, SooHoo NF. Which factors influence preservation of the osteonecrotic femoral head. Clin Orthopaed Related Res. 2012;470(2):525–34. DOI: https://doi.org/10.1007/s11999-011-2050-4

Ficat RP. Idiopathic bone necrosis of the femoral head. Early diagnosis and treatment. J Bone Joint Surg Br. 1985;67(1):3-9. DOI: https://doi.org/10.1302/0301-620X.67B1.3155745

Mont MA, Jones LC, Hungerford DS. Nontraumatic osteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2006;88(5):1117-32. DOI: https://doi.org/10.2106/JBJS.E.01041

Urbaniak JR, Coogan PG, Gunneson EB, Nunley JA. Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips. J Bone Joint Surg Am. 1995;77(5):681-94. DOI: https://doi.org/10.2106/00004623-199505000-00004

Marker DR, Seyler TM, Ulrich SD, Srivastava S, Mont MA. Do modern techniques improve core decompression outcomes for hip osteonecrosis. Clin Orthopaed Related Res. 2008;466(5):1093–103. DOI: https://doi.org/10.1007/s11999-008-0184-9

Rajagopal M, Balch Samora J, Ellis TJ. Efficacy of core decompression as treatment for osteonecrosis of the hip: a systematic review. Hip Int. 2012;2(5):489-93. DOI: https://doi.org/10.5301/HIP.2012.9748

Kang JS, Moon KH, Kim BS, Kwon DG, Shin SH, Shin BK, et al. Clinical results of auto-iliac cancellous bone grafts combined with implantation of autologous bone marrow cells for osteonecrosis of the femoral head: a minimum 5-year follow-up. Yonsei Med J. 2013;54(2):510-5. DOI: https://doi.org/10.3349/ymj.2013.54.2.510

Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orthop Relat Res. 2002;(405):14-23. DOI: https://doi.org/10.1097/00003086-200212000-00003

Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489-96. DOI: https://doi.org/10.1016/j.joms.2003.12.003

Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009;37(11):2259-72. DOI: https://doi.org/10.1177/0363546509349921

Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28(31):4551-60. DOI: https://doi.org/10.1016/j.biomaterials.2007.06.037

Houdek MT, Wyles CC, Smith JH, Terzic A, Behfar A, Sierra RJ. Hip decompression combined with bone marrow concentrate and platelet-rich plasma for corticosteroid-induced osteonecrosis of the femoral head: mid-term update from a prospective study. Bone J Open. 2021;2(11):926-931. DOI: https://doi.org/10.1302/2633-1462.211.BJO-2021-0132.R1

Piuzzi NS, Chahla J, Jiandong H, Chughtai M, LaPrade RF, Mont MA, et al. Analysis of cell therapies used in clinical trials for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplasty. 2017;32(8):2612-8. DOI: https://doi.org/10.1016/j.arth.2017.02.075

Hernigou P, Verrier S, Homma Y, Rouard H, Lachaniette CHF, Sunil Kumar KH. Prognosis of hip osteonecrosis after cell therapy with a calculator and artificial intelligence: ten-year collapse-free survival prediction on three thousand and twenty-one hips. Int Orthop. 2023;47(7):1689-705. DOI: https://doi.org/10.1007/s00264-023-05788-9

Samy AM. Management of osteonecrosis of the femoral head: A novel technique. Indian J Orthop. 2016;50(4):359-65. DOI: https://doi.org/10.4103/0019-5413.185590

Haixia Xu, Chengqiang Wang, Chun Liu, Ziyue Peng, Jianjun Li, Yanglei Jin, et al. Cotransplantation of mesenchymal stem cells and endothelial progenitor cells for treating steroid-induced osteonecrosis of the femoral head, stem cells. Translational Med. 2021;10(5):781–96. DOI: https://doi.org/10.1002/sctm.20-0346

Zheng C, Wu Y, Xu J, Liu Y, Ma J. Exosomes from bone marrow mesenchymal stem cells ameliorate glucocorticoid-induced osteonecrosis of femoral head by transferring microRNA-210 into bone microvascular endothelial cells. J Orthopaed Surg Res. 2023;7;18(1):96. DOI: https://doi.org/10.1186/s13018-023-04440-x

Ma B, Wang T, Li J, Wang Q. Extracellular matrix derived from Wharton’s Jelly-derived mesenchymal stem cells promotes angiogenesis via integrin αVβ3/c-Myc/ P300/VEGF. Stem Cell Res Therapy. 2022;13(1):794. DOI: https://doi.org/10.1186/s13287-022-03009-5

Agarwala S, Shah S, Joshi VR. The use of alendronate in the treatment of avascular necrosis of the femoral head: follow-up to eight years. J Bone Joint Surg Br. 2009;91(8):1013-8. DOI: https://doi.org/10.1302/0301-620X.91B8.21518

Arai R, Takahashi D, Inoue M, Irie T, Asano T, Konno T, et al. Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head: a retrospective comparative study with alendronate. BMC Musculoskelet Disord. 2017;18(1):24. DOI: https://doi.org/10.1186/s12891-016-1379-y